Denmark - August 6, 2025
Novo Nordisk lowers sales and operating profit outlook for 2025 and makes organizational changes
Novo Nordisk has announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and operating profit outlook at CER.
Pharma Business - August 4, 2025
Purpose Pharma receives European Commission approval of ATTROGY
The European Commission has granted ATTROGY (diflunisal) marketing authorization for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Collaboration - July 29, 2025
Neuraxpharm and Dizlin Pharmaceuticals enter co-development agreement
Neuraxpharm Group and Swedish Dizlin Pharmaceuticals have announced a strategic global co-development agreement for Infudopa SubC.
Global report - July 28, 2025
AstraZeneca plans to invest USD 50 billion in US manufacturing and R&D
This investment is expected to create tens of thousands of new jobs across the country states the company.
Financing - July 28, 2025
Gesynta Pharma raises SEK 347 million
The company has raised an additional SEK 43 million in its Series B second closing, bringing the total Series B capital to SEK 347 million.
Pharma Business - July 17, 2025
AlzeCure’s pain project granted orphan drug status in the US
The US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440.
